Investors

Home » investors » Corporate Information » Corporate Profile

Corporate Profile



Investor Tools

  • Email page
  • PDF view
  • Print view
  • Email Alert
  • RSS Feeds
  • Tearsheet
  • Mobile IR Site
  • Social Media Sharing
  • Email page
  • PDF view
  • Print view
  • Email Alert
  • RSS Feeds
  • Tearsheet
  • Mobile IR Site
  • Social Media Sharing

Stock Quote

  • NASDAQCNDO
  • Market Value ($M)71.28
  • Change ($)(0.06)
  • Change (%)(2.78)
  • Volume115,684
  • Stock Quote ($)2.10
As of August 29, 2014 - Minimum 20 minute delay.

Webcast
Coronado Biosciences TRUST-I Study Results Call
Monday, October 14, 2013
9:00 AM ET
Since inception, Coronado Biosciences has been a biopharmaceutical company involved in the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, namely CNDO-201 or Trichuris suis ova (TSO) and CNDO-109. As part of its growth strategy, the Company plans to identify, evaluate and potentially in-license, acquire or invest in pharmaceutical and biotechnology products, technologies and/or companies. Coronado may also from time to time consider financing existing or later-acquired products, technologies or companies through partnerships, joint ventures, direct financings and/or public or private spin-outs.

Contact Information

Coronado Biosciences, Inc.
24 New England Executive Park
Suite 105
Burlington, MA 01803
Phone: (781) 652-4500
Fax: (781) 652-4545
info@coronadobio.com

Investor Relations
Lucy Lu, M.D., EVP & CFO
ir@coronadobio.com
(781) 652-4525
All Releases